Zwift, a Long Beach, Calif.-based provider of an app that connects cyclists and runners in 3D computer-generated worlds, scored $450 million in Series C funding. KKR & Co. led the investment, which gives the company a valuation of more than $1 billion. New investors Permira, Amazon Alexa Fund and Specialized Bicycle Components' venture fund also participated in the round, along with previous backers True, Highland Europe, Novator and Causeway Media.
PrognomIQ Inc., a developer of tests for cancer and other complex diseases, has spun out of Seer Inc. and secured a $55 million investment. The round was led by aMoon, and included participation from Fidelity Management & Research Co., funds and accounts advised by T. Rowe Price Associates Inc., Invus, Maverick Ventures, Emerson Collective, Wing VC and Bruker Corp. Seer will retain a minority ownership position in PrognomIQ, and Philip Ma, founder and former chief business officer of Seer, was named chief executive of the new company. Tomer Berkovitz, partner and chief financial officer at aMoon, will join PrognomIQ’s board.
Ready, a New Orleans-based on-demand healthcare service, closed a $54 million Series C round from investors including GV, Deerfield Management Co., City Light Capital, Town Hall Ventures and Frist Cressey Ventures.
Hexagon Bio Inc., a Menlo Park, Calif.-based startup using DNA sequencing of fungal genomes to discover novel disease and cancer treatments, completed a $47 million Series A round. The Column Group led the investment, which included participation from 8VC and Two Sigma Ventures. Additionally, the company appointed Tod Smeal as chief scientific officer. He was most recently at Lilly Research Labs. David Goeddel, managing partner at The Column Group, will join as chairman of Hexagon’s board.
Graphite Bio, a South San Francisco, Calif.-based gene editing startup, collected $45 million in Series A financing. Versant Ventures led the round, and was joined by Samsara BioCapital. The company also appointed Josh Lehrer as chief executive. He was most recently chief medical officer at Global Blood Therapeutics. Samsara BioCapital’s Abe Bassan and Versant’s Carlo Rizzuto joined the board.
Medigate, a Brooklyn, N.Y.-based startup focusing on cybersecurity for medical devices, landed a $30 million Series B round. Partech led the investment, which included contributions from YL Ventures, U.S. Venture Partners, Blumberg Capital and Maor Investments.
Attralus Inc., a South San Francisco, Calif.-based developer of medicines to treat systemic amyloidosis, closed a $25 million Series A round led by venBio Partners. Richard Gaster and Corey Goodman, venBio partner and managing partner, respectively, joined the board.
Aidoc, a Tel Aviv-based provider of artificial intelligence technology to radiologists, added $20 million in Series B financing, bringing the round total to $47 million. New investors Alpha Intelligence Capital and Maor Investments provided the new funding, along with previous backers Square Peg Capital, TLV Partners, Magma Ventures and Emerge.
Rejoni Inc., a Bedford, Mass.-based developer of gynecological products using its proprietary biomaterials, snagged $15 million in Series A funding. Ascension Ventures led the round, and was joined by Delos Capital and Sparta Group. Tara Butler, a managing director at Ascension Ventures, will join the board.
CoreMap, a Burlington, Vt.-based developer of diagnostic technology to enable curative treatment options and improve outcomes for patients with atrial fibrillation, closed a $10.5 million Series A round. Qure Ventures led the investment, with Managing Partner Allen Kamer joining the board. Ronny Ginor, venture partner at Orbimed, also participated in the funding round, and was added to the board.
Ansa Biotechnologies Inc., a Berkeley, Calif.-based DNA synthesis technology startup, was seeded with a $7.9 million investment. Horizons Ventures led the round, with participation from Mubadala Capital, Humboldt Fund and others.
Stemson Therapeutics, a San Diego-based hair regeneration therapy startup, picked up a $7.5 million seed investment led by Allergan Aesthetics and Fortunis Capital.
|